Blood component therapy in postpartum hemorrhage.

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Transfusion Medicine

Background:

• Postpartum hemorrhage (PPH) is a significant cause of maternal morbidity and mortality worldwide.
• Effective management of PPH relies on timely and appropriate interventions, including blood component therapy.

Purpose of the Study:

• To investigate the utilization and outcomes of blood component therapy in patients diagnosed with postpartum hemorrhage.
• To assess the safety and efficacy of blood component transfusion in managing severe PPH.

Main Methods:

• Retrospective review of delivery records at Duke University Medical Center from 2000-2004.
• Identification of patients with PPH using ICD-9 codes (666.0X, 666.1X, 666.2X).
• Analysis of blood component transfusion data and patient outcomes, including mortality and organ dysfunction.

Main Results:

• Out of 12,476 deliveries, 5.4% (671) had PPH; 0.87% (108) required blood component therapy.
• Red blood cells (RBCs) were transfused in 106 patients; 30 received non-RBC components (fresh-frozen plasma, cryoprecipitate, platelets).
• No patients received hemostatic agents; no thromboembolic events, deaths, or organ dysfunction occurred.

Conclusions:

• Readily available blood component therapy at a major US medical center was associated with excellent outcomes in severe PPH.
• Modern blood banking capabilities can effectively mitigate the risks of mortality and organ dysfunction in PPH cases.
• The study highlights the critical role of timely blood product transfusion in managing obstetric emergencies.